Answers are grounded in this paper and cite their sources.
New antifungals, ibrexafungerp and oteseconazole, are now available for treatment of vulvovaginal candidiasis. Both have novel antimicrobial and pharmacokinetic properties and advantages over fluconazole, although comparative trials have involved only placebo. In the absence of allergy, intolerance, and resistance, it is unclear whether these antifungals will replace fluconazole.
No takes yet. Share an insight, caveat, or question.
Jack D. Sobel (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: